The October Dividend Power list highlights stocks like Invesco Mortgage Capital and MFA Financial for their high dividend yields and 'safer' dividends backed by free cash flow. These top ten stocks are projected to deliver average net gains of 86.23% by October 2027, with analyst targets suggesting significant upside potential ranging from 68.12% to 152.55%. The Dividend Power strategy focuses on underpriced, high-yielding stocks that provide resilient income in various market conditions. Seven of the 35 Dividend Power stocks maintain dividends well-covered by free cash flow, indicating financial stability, although only Barings BDC showed price appreciation over the past year.
The October Dividend Power Dogs list projects average net gains of 86.23% by October 2027. For readers following Financials-sector US stocks on Pluang, here is the market snapshot as of Oct 14, 2026 21:41 WIB: out of 142 priced stocks, 7 rose and 135 fell. Notable movers include MARA at USD 8.56 with a -5.98% change and 100% buy order activity, RIOT at USD 15.70 with a -5.85% change and 66% buy order activity, and PURR at USD 9.67 with a -5.47% change and a typical hold time of 5 days.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
